FFO
KYMR icon

Fortitude Family Office’s Kymera Therapeutics KYMR Stock Holding History

Fortitude Family Office’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7K Hold
41
– – ﹤0.01% 1104
2026
Q1 		$3.42K Buy
41
+20
+95% +$1.58K ﹤0.01% 1075
2025
Q4 		$1.63K Buy
21
+3
+17% +$203 ﹤0.01% 1258
2025
Q3 		$1.02K Hold
18
– – ﹤0.01% 1543
2025
Q2 		$786 Buy
+18
New +$620 ﹤0.01% 1616

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fortitude Family Office's KYMR Position: Q2 2026 in Review

Fortitude Family Office held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 41 shares worth $4.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1104.

Fortitude Family Office first reported a position in KYMR in Q2 2025 and has held it in 5 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Fortitude Family Office held 41 shares of Kymera Therapeutics worth $4.7K as of Q2 2026.
  • Fortitude Family Office left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1104 holding.
  • Fortitude Family Office first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.